What Prolastat Treats: Main Uses and Benefits

Prolastat is commonly used across conditions presenting with symptoms related to systemic imbalance, which may include those stemming from hormonal factors. It is relevant for easing symptom clusters associated with three primary areas: management of conditions such as prolactin-secreting pituitary tumors (prolactinomas), addressing reproductive and menstrual irregularities, and easing unwanted breast milk production (galactorrhea).

This treatment is applied in situations involving certain distressing symptoms and may assist in normalizing systemic imbalance. It helps address symptom clusters that interfere with daily comfort and supports general well-being during symptomatic phases. This supportive relief contributes to improved day-to-day comfort. The medication is generally used in clinical settings that involve acute or unstable symptom patterns where supportive symptomatic assistance is needed.

---

Quick Fact: Relief for Hormonally-Driven Symptoms

Regulatory References

1. NHS Foundation Trust guidance on Cabergoline Treatment

Eligibility Map: Who Can and Cannot Use Prolastat — Official Regulatory Information

Eligibility scope

Category	Official Regulatory Statement
Populations for whom use is allowed (as stated in label)	Adults with hyperprolactinemic disorders (idiopathic or due to pituitary adenoma).
Populations for whom use is contraindicated	Patients with uncontrolled hypertension; known hypersensitivity to cabergoline or any ergot derivative; a history of pulmonary, pleural, pericardial, or retroperitoneal fibrotic disorders; and cardiac valvulopathy confirmed by echocardiogram.
Age-related eligibility rules	Safety and effectiveness are not established in pediatric patients (under 16 years of age). Use in older adults is limited, requiring careful dosage selection.
Condition-specific eligibility rules	Contraindicated in women with pre-eclampsia, eclampsia, or post-partum hypertension. Use requires caution in patients with severe cardiovascular disease and a history of serious psychotic mental disorders.
Pregnancy and lactation eligibility status (if explicitly documented)	Pregnancy: Use is only if clearly needed; discontinuation is advised upon conception. Lactation: Breastfeeding should be avoided as the drug interferes with milk production.

Connection to the overall eligibility profile

Regulatory documents strictly define eligibility by mandating absolute contraindications based on the drug's ergot-derivative class and the risk of fibrotic complications, especially concerning heart valves. The use is largely limited to adults for hyperprolactinemic conditions, while specific restrictions apply to organ function, such as considering lower doses for those with severe hepatic insufficiency.

Interactions with other medicines and products

The official regulatory profile for Cabergoline identifies specific interactions structured by pharmacodynamic effects and exposure modification.

Contraindicated Combinations and Antagonism

Co-administration with Dopamine (D2) Antagonists (including metoclopramide and certain antipsychotic agents like phenothiazines) is not recommended due to the potential for pharmacodynamic antagonism, which directly counteracts the intended effect. Furthermore, the combination with other Ergot Derivatives must be avoided to prevent the documented risk of cumulative toxicity.

Caution and Exposure Modification

Caution is advised when co-administering Cabergoline with Antihypertensive Agents because of the risk of additive effects resulting in an increased incidence of orthostatic hypotension. Caution is also advised regarding the consumption of alcohol due to the possibility of additive central nervous system effects. Food does not alter the pharmacokinetics of Cabergoline.

Metabolic and Population Constraints

Cabergoline metabolism occurs primarily through hydrolysis; CYP-450 mediated metabolism is minimal and not expected to cause significant enzyme inhibition or induction. A population-specific pharmacokinetic constraint is officially documented: individuals with severe hepatic insufficiency exhibit a substantial increase in systemic drug exposure (AUC and Cmax).

Augmenting the Protease-Antiprotease Ratio

Prolastat (Alpha-1 Proteinase Inhibitor) functions via protein augmentation, introducing exogenous Alpha-1 Proteinase Inhibitor (A1PI) to increase its plasma and pulmonary concentrations. This elevates the concentration of A1PI to neutralize its primary biological target, the destructive enzyme neutrophil elastase (NE), which results in the inhibition of neutrophil elastase activity and the re-establishment of the A1PI / NE activity ratio.

---

Targeting the Destructive Proteolytic Cascade

The drug's active component engages mechanisms that directly and irreversibly inhibit the activity of neutrophil elastase, the enzyme operating within the proteolytic cascade. By blocking this molecular step, Prolastat intervenes in the overactive degradation process, which directly reduces the uncontrolled activity of neutrophil elastase and decreases the proteolytic degradation of elastin molecules.

---

Modulating Localized Pulmonary Activity

Prolastat acts to modulate overactive or dysregulated proteolytic processes within the local lung environment. Following systemic delivery, the A1PI modifies enzyme dynamics in the peripheral pathways by sustaining inhibitory concentrations at the alveolar surface. This results in a modulated state within the targeted pathways, which influences the functional status of the lung's extracellular matrix components.

Prolastat (cabergoline) is administered by the oral route using the 0.5 mg tablet form. The primary principle of usage is to identify and maintain the lowest effective weekly dose required to achieve and sustain the normalization of serum prolactin levels.

For chronic hyperprolactinemic disorders, therapy is typically initiated with a low dose of 0.25 mg taken twice a week. The dose may be gradually increased by 0.25 mg twice weekly increments, but these adjustments are made no more frequently than every 4 weeks. Dosing rules may vary; for instance, the maximum recommended dose is 1 mg twice weekly (2 mg/week), while higher total weekly doses have been used in some instances. When the total weekly dose exceeds 1 mg, it is typically advised to divide the amount into multiple administrations to support patient tolerability.

The tablets may be taken with or without food, though taking them with meals is also suggested. Administration is closely monitored by checking serum prolactin levels at monthly intervals during the titration phase. If prolactin levels remain normalized for six continuous months, the medicine may be discontinued to assess if further therapy is necessary.

Specific population considerations include using caution in patients with severe hepatic impairment and advising that older adults start treatment at the lower end of the initial dosing range. The safety and efficacy of Prolastat have not been established in pediatric patients.

Evidence for Use in Hyperprolactinemic Disorders and Prolactinomas

Studies have explored the use of Prolastat in individuals with elevated prolactin levels, including those with prolactin-secreting pituitary tumors (prolactinomas). Research examined various adult populations, including those previously identified as intolerant or resistant to other treatments. The study types available include randomized controlled trials (RCTs) and large-scale cohort studies that monitored patient groups over time. Research monitored the level of serum prolactin (PRL) and changes in pituitary tumor volume. Data show patterns related to the normalization of serum prolactin levels across the observed groups. Research also described patterns of tumor volume change observed in some study populations.

---

Evidence for Symptomatic Hormonal Disturbances

Research has explored the medicine’s use in patient populations with symptomatic disturbances that often arise from elevated prolactin. These studies primarily involved adult women and monitored key endpoints, including the assessment of resolution of menstrual irregularity (addressing amenorrhea or oligomenorrhea) and the cessation of unwanted breast milk production (galactorrhea). In comparative trials, studies reported patterns where the resolution of menstrual irregularity and unwanted breast milk production was measured and tracked across the study groups. The status of the menstrual cycle and ovulatory cycles was also measured during the follow-up periods.

---

Long-Term Outcomes, Subgroups, and Evidence Gaps

Studies explored the durability of the hormonal response through intermediate- and long-term observational settings, monitoring the recurrence rates after treatment discontinuation. Subgroup analyses explored findings for patients with macroprolactinomas separately from microprolactinomas, as well as those who were treatment resistant. Data show patterns related to the lack of established long-term effects. Follow-up durations were limited in many controlled trials, meaning long-term effects are not fully established. Comparative evidence against placebo is lacking for certain outcomes, and data for some groups, such as pediatric populations, remain insufficient for a full assessment.

Key Studies & References Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis

Common questions about Prolastat (FAQ)

Q: What is the specific maximum length of time an unopened vial of Prolastat can be stored at room temperature?

According to the official product information for the Alpha-1 Proteinase Inhibitor formulation of Prolastat, an unopened vial must typically be refrigerated. However, official labeling permits it to be kept at room temperature (up to 25 C or 77 F) for a single, maximum period of 30 days. After this 30-day period, the vial must be discarded, even if it has not been opened.

Q: What is the primary way Prolastat is eliminated from the body?

Official pharmacological data for the active ingredient, Cabergoline, indicates that the drug is mainly eliminated from the body through waste products. The majority of the drug and its byproducts are excreted through the feces, accounting for about 60% of the dose. A smaller portion is removed through the urine.

Q: Can I drink alcohol while taking Prolastat?

Regulatory documents note that caution is advised regarding alcohol consumption alongside Cabergoline. Alcohol may increase the central nervous system side effects of the medication. This could lead to a higher risk of experiencing effects such as dizziness or drowsiness.

Q: Why is Prolastat not recommended for patients with a history of heart problems?

The medication is part of a drug class known as ergot derivatives, which is associated with a risk of causing fibrotic reactions, or scarring of tissue. For this reason, official prescribing information states that the drug is contraindicated (should not be used) in patients who have a history of heart valve damage (cardiac valvulopathy) or certain fibrotic disorders.

Q: What is Prolastat used for in men?

The official indication for Prolastat (Cabergoline) is for the treatment of hyperprolactinemic disorders, which is a condition characterized by high levels of the hormone prolactin. This includes cases where the elevated prolactin is caused by a pituitary tumor or is of unknown origin, and the treatment applies to adult men as well as women.

Q: How quickly does Prolastat start working to lower prolactin levels?

Official clinical monitoring information indicates that Cabergoline begins to suppress prolactin secretion soon after administration. The normalization of serum prolactin levels is typically observed within two to four weeks after the appropriate therapeutic dose has been established.

How to Store and Dispose of Prolastat?

Prolastat (alpha-1 proteinase inhibitor) requires specific handling and storage to maintain its stability and effectiveness, as documented in official labeling.

Condition	Requirement
Unopened Storage	Refrigerate vials between 2 C to 8 C (36 F to 46 F). Do not freeze the product.
Room Temperature	Unopened vials may be kept at room temperature (up to 25 C) for a single, maximum period of 30 days, after which the vial must be discarded.
Post-Reconstitution	The mixed solution must be administered within 3 hours if stored at 20 C to 25 C and protected from light.
Disposal	As the product is a single-use vial with no preservative, any unused portion of the reconstituted solution must be discarded. Needles, syringes, and used vials must be disposed of in a puncture-resistant container according to local environmental regulations. Always keep the product out of the reach of children.